BioNexus Gene Lab shares rise 36.85% premarket after securing $500M equity facility with ARC Group to fund diagnostics and CDMO expansion.

BioNexus Gene Lab Corp. surged 36.85% in premarket trading following the announcement of a $500 million equity facility with ARC Group International and an exclusive Southeast Asia licensing agreement for the VitaGuard™ MRD platform. The equity facility provides discretionary capital to advance diagnostics commercialization, CDMO expansion, and therapeutic programs, while the licensing agreement grants perpetual rights to a next-generation liquid biopsy platform, enhancing BGLC’s market position in oncology diagnostics. Both events signal strategic growth acceleration and financial flexibility, directly aligning with the stock’s sharp premarket rise.